Tim Lugo

Tim Lugo

+1 312 364 8415
E-mail vCard

Specialties:  Therapeutics

Tim Lugo, partner, joined William Blair in 2005 and focuses on the therapeutics space. Before joining William Blair, he worked at Pacific Growth Equities as a junior analyst on a number of specialty pharmaceutical companies. Mr. Lugo was named No. 1 stock picker and No. 3 earnings estimator in the 2016 Thomson Reuters Analyst Awards for his coverage of biotechnology. Mr. Lugo has a B.A. in molecular and cellular biology (with an emphasis in genetics) and a B.A. in economics, both from the University of California, Berkeley.

Acer Therapeutics Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Acer Therapeutics Inc. (ACER $17.00), a biopharmaceutical company focused on the development of treatments for rare diseases. Learn More

Ovid Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd.: Initiation of Research Coverage

William Blair & Company initiated research coverage of two small-cap therapeutics companies focused on neurologic diseases: Ovid Therapeutics Inc. (OVID $14.57) and Biohaven Pharmaceutical Holding Company Ltd. (BHVN $23.79). Learn More

Akari Therapeutics, PLC: Initiation of Research Coverage

William Blair & Company initiated research coverage of Akari Therapeutics, PLC (AKTX $11.62). Akari Therapeutics is a development-stage biotechnology company focused on development of next-generation complement inhibitors for the treatment of rare hematologic diseases. Learn More